

Journal of Visualized Experiments

Investigation of the mechanisms underlying gut hormone secretion using isolated perfused rat small intestine --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58533R2
Full Title:	Investigation of the mechanisms underlying gut hormone secretion using isolated perfused rat small intestine
Keywords:	Isolated perfused rat small intestine gut hormone secretion molecular sensors
Corresponding Author:	Rune Ehrenreich Kuhre, Ph.D, MSc University of Copenhagen Copenhagen N, DENMARK
Corresponding Author's Institution:	University of Copenhagen
Corresponding Author E-Mail:	kuhre@sund.ku.dk
Order of Authors:	Rune Ehrenreich Kuhre, Ph.D, MSc Jens Juul Holst
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Faculty of Health and Medical Sciences, Blegdamsvej 3B, bygn. 12.2, Copenhagen N, Denmark

DEPARTMENT OF BIOMEDICAL SCIENCES
UNIVERSITY OF COPENHAGEN

Editors of Journal of Visualized experiments



Dear editors

Please find attached our invited manuscript entitled 'Investigation of the mechanisms underlying gut hormone secretion using isolated perfused rat small intestine', which we hope will be judged suitable for publication in your journal.

This invited manuscript was encouraged by your Senior Science Editor Dr. Singh who came across our isolated perfused rat small intestine perfusion method in our recent work in Molecular Metabolism (Pubmed id: 29656109) and encouraged us to submit a paper to your journal detailing the method.

We here provide a detailed description of the method from an experimental point of view and have, in addition, chosen to include an introduction that details the benefits of this method compared to other methods for studying gut hormone secretion.

As clearly described in the manuscript, this method is a robust method for studying hormone secretion. Nevertheless, based on published work within the field of gut hormones it appears that very few other groups are working with this method. We therefore, welcome this opportunity to spread the knowledge about this method to fellow scientists.

Sincerely,

Rune Ehrenreich Kuhre and Jens Juul Holst

JANUARY 30 2017

ENDOCRINOLOGY & METABOLISM

BLEGDAMSVEJ 3, DK 2200 ,
COPENHAGEN N, DENMARK

DIR 28757518
MOB 28757518

j.jholst@sund.ku.dk

REF: JJH

TITLE:

Mechanisms Underlying Gut Hormone Secretion using the Isolated Perfused Rat Small Intestine

AUTHORS AND AFFILIATIONS:

Rune E. Kuhre and Jens J. Holst

Department of Biomedical Sciences and NNF Centre for Basic Metabolic Research, the Panum Institute, University of Copenhagen, Copenhagen, Denmark.

Email Addresses of Co-Authors:

Rune E. Kuhre (Kuhre@sund.ku.dk)

Jens Juul Holst (jjholst@sund.ku.dk)

Corresponding author:

Rune E. Kuhre (Kuhre@sund.ku.dk)

KEYWORDS:

Isolated perfused rat small intestine, molecular sensors, gut hormone secretion, nutrient absorption, intact cellular polarization, glucagon-like peptide-1, methods for studying gut hormone secretion.

SHORT ABSTRACT:

Here, we present a powerful and physiological model to study the molecular mechanisms underlying gut hormone secretion and intestinal absorption – the isolated perfused rat small intestine.

LONG ABSTRACT:

The gut is the largest endocrine organ of the body, producing more than 15 different peptide hormones that regulate appetite and food intake, digestion, nutrient absorption and distribution, and post-prandial glucose excursions. Understanding the molecular mechanisms that regulate gut hormone secretion is fundamental for understanding and translating gut hormone physiology. Traditionally, the mechanisms underlying gut hormone secretion are either studied *in vivo* (in experimental animals or humans) or using gut hormone-secreting primary mucosal cell cultures or cell lines. Here, we introduce an isolated perfused rat small intestine as an alternative method for studying gut hormone secretion. The virtues of this model are that it relies on the intact gut, meaning that it recapitulates most of the physiologically important parameters responsible for the secretion in *in vivo* studies, including mucosal polarization, paracrine relationships and routes of perfusion/stimulus exposure. In addition, and unlike *in vivo* studies, the isolated perfused rat small intestine allows for almost complete experimental control and direct assessment of secretion. In contrast to *in vitro* studies, it is possible to study both the magnitude and the dynamics of secretion and to address important questions, such as what stimuli cause secretion of different gut hormones, from which side of the gut (luminal or vascular) is secretion stimulated, and to analyze in detail molecular sensors underlying the secretory response. In addition, the preparation is a powerful model

for the study of intestinal absorption and details regarding the dynamics of intestinal absorption including the responsible transporters.

INTRODUCTION:

The gut is the largest endocrine organ of the body, producing more than 15 different peptide hormones that regulate nutrient absorption and nutrient disposition, intestinal growth and modulate appetite¹. Gut hormones are, therefore, involved in many fundamental physiological processes, and understanding these patterns of secretion and the molecular details that control secretion of the respective hormones is thus important for our basic physiological understanding and for addressing translational aspects of gut hormone actions; but how can one study the molecular sensing mechanisms underlying gut hormone secretion? In general, hormone secretion can be studied in intact organisms (humans or experimental animals), from isolated gut preparations or from gut hormone-secreting primary cell cultures or immortalized cell cultures²⁻⁶. Our preferred model is the isolated perfused rat small intestine, which is a physiologically relevant model that allows the secretion of gut hormones to be studied in detail with optimal time resolution (secretion rates can be determined with any time base down to the second), and the results are likely transferrable to an *in vivo* situation⁷. Here, we provide a detailed protocol on how to perform this procedure, but first we will discuss other methods for studying gut hormone secretion, including the benefits and limitations of these models compared to the isolated perfused rat small intestine.

If one wishes to establish whether a specific compound regulates the secretion of certain gut hormones, studies in humans are the ultimate goal. Thus, if a compound shows great effects on the secretion of one or several gut hormones in rodents (*in vivo* or perfusions) or from hormone secreting cells (cell lines or primary cells), this effect is only relevant to medicine and human physiology if it can be confirmed in humans. However, there are clear limits for the type of studies that can be performed in humans, and *in vivo* studies on experimental animals are, therefore, often the second-best option for such studies. Mice and rats are the most frequently used experimental animals presumably due to their convenient size, low cost and the option to genetically alter the genes suspected of being involved in the specific study questions (*e.g.*, knock out of a certain transporter or receptor). In general, *in vivo* models benefit from being physiologically intact, but also have several limitations. Most importantly, the small size of rodents, particularly mice, is a limiting factor, as most assays for gut hormone quantification require at least 20 μ L of plasma (and often much more), meaning that at least 100 μ L of blood has to be withdrawn to make a duplicate quantification. Therefore, it is only possible to obtain very few samples corresponding to baseline samples and one or two post-stimulation samples (the total blood volume in a mouse of 20 g is \sim 1.4 mL). Consequently, potential secretory responses (*e.g.*, rapidly or late-occurring responses) may therefore be missed.

In the perfusion model, this issue is overcome, as large sample volumes are obtained (flow rate: 7.5 mL/min) and the collection intervals can be adjusted as needed to ensure that the rapid and short-lasting responses are not missed (we collect samples every min)⁷. Another issue with *in vivo* studies in rodents is that most gut hormones are even more rapidly eliminated or metabolized than in humans⁸⁻¹⁰, which may complicate the subsequent biochemical analysis. For instance, we showed that GLP-1 is

metabolized in mice at an even faster rate than in humans (where $T_{1/2}$ is 1-2 min¹¹) and, more importantly, that the cleavage of GLP-1 in mice involves, in addition to N-terminal cleavage by dipeptidyl-peptidase-4 (DPP4) (which is the major GLP-1 degrading enzyme in humans), further cleavage by the enzyme neutral endopeptidase 24.11⁸. Consequently, current commercial assays for the quantification of GLP-1, which are either based on the intact isoform of GLP-1 (7-36amide) or the DPP-4 cleaved isoform (9-39amide), vastly underestimate GLP-1 secretion in mice and result in misleading results¹². In the isolated perfused rat small intestine, most of the metabolism of secreted hormones is eliminated or markedly reduced, since plasma-mediated degradation is avoided, and liver/kidney/lung extraction/degradation is prevented (because perfusate is collected as it leaves the gut).

Of course, important insight can be generated by the use of genetically modified animals, *e.g.*, sodium-glucose transporter-1 knockout mice¹³, but a detailed assessment of the molecular sensors involved in secretion often requires consideration of multiple molecular sites, ranging from molecular transporters to ion channels and from different G-protein-coupled receptors to intracellular proteins. For instance, we targeted the activity of nine different molecular sites when unraveling the molecular sensors responsible for glucose-stimulated GLP-1 secretion⁷. A similar investigation would not be possible *in vivo* as some of the compounds used have unspecific or harmful/lethal effects. For instance, when using the perfused gut, it was possible to assess the role of intra-cellular glucose metabolism for the secretion of GLP-1 and neurotensin by blocking ATP formation with 2,4-dinitrophenol^{7,14} as well as the role of voltage-gated calcium channels for bile acid stimulated GLP-1, NT and PYY secretion³. Indeed, the highly toxic sodium channel blocker tetrodotoxin can be successfully applied in the perfusion studies. Finally, in the perfusion model it can be directly assessed where in the gut a certain compound stimulates secretion of a certain hormone, as the investigator can simply choose and prepare the desired region to perfuse, and at the same time it can be investigated whether a stimulus causes secretion by activation of molecular sensors from the luminal or vascular side of the intestine^{3,15,16}.

The secretory mechanisms underlying gut hormone secretion may also be studied by use of gut tissue pieces (including human tissue), primary intestinal cultures (usually from mice), immortalized hormone secreting cell lines (of mouse or human origin), by gut tissue mounted in Ussing chambers or by organoids (both most often from mice)^{2-6,17,18}. Compared to intestinal perfusions, studies on human gut pieces, primary cell cultures and cell lines are technically easier to perform and are a faster and cheaper way of generating data, but of course the study of gut pieces requires access to fresh human gut specimens. However, in these models the normal cell polarization of the gut is inherently lost, meaning that these models cannot be used to assess normal activation of molecular sensors, and absorption processes also cannot be studied. Moreover, such studies usually employ static incubations (for up to several h) which is highly non-physiological and has nothing to do with the cells' normal secretory dynamics, because the secreted product is not removed and thus may feedback influence the secretion of hormones. In contrast, in the perfused intestine, secreted and absorbed molecules are efficiently removed by the mucosal microcirculation as they are *in vivo*, ensuring that the transmucosal gradients are maintained so absorption and secretion can occur at a normal rate.

Furthermore, cell cultures may have dedifferentiated from their native enteroendocrine cell origin, meaning that they are no longer representative of the native cells in terms of peptide content and expression of molecular sensors, although they may still secrete the hormone in question. This is, for instance, the case for GLP-1 secreting cell lines¹⁹.

It is, therefore, our opinion that primary cell cultures or cell line studies are most suited for screening purposes and for performing types experiments that cannot be performed *in vivo* or in the isolated perfused gut. For instance, a true strength of the primary cell cultures and cell line cultures is that intra-cellular secondary messengers (Ca^{2+} , cAMP, NAD(P)H) can be monitored in real time, and electrical signaling of the hormone secreting cells can be investigated²⁰⁻²². In addition, siRNA knockdown can be done, which is particularly useful if specific inhibitors are not available²⁰⁻²⁴. Gut tissue from mice mounted in Ussing chambers has recently been used for studying the molecular mechanisms underlying bile-acid stimulated GLP-1 secretion, while intestinal organoids (from mice) and human gut pieces have also been used for studying the molecular details of gut hormone secretion^{17,25}. Whereas the former benefits from being polarized² all of these models involve static incubations. Studies on human gut pieces, however, benefit from using human, rather than rodent, tissue which is important since species difference in tissue expression of 7TM receptors and molecular transporters may result in different molecular sensing pathways between species. In fact, most data in this field has been generated by studies on either pigs, mice or rats, and it remains elusive whether these findings can be transferred to humans. It is, however, reassuring that the molecular sensing mechanisms that underlie glucose-stimulated GLP-1 secretion appear to be similar between mouse, rat and man^{7,18,26}.

The isolated perfused rat small intestine, however, also has some limitations that should be considered. Most importantly, it is impossible to determine whether a given secretory response results from direct activation by the test substance of the targeted hormone-producing cells or rather is caused by an indirect mechanism. For instance, KCl instantly increases GLP-1 secretion from the perfused intestine⁷, but it remains unknown whether this is a consequence of direct depolarization of the L-cell or results from depolarization of neurons close to the L-cells or effects of simultaneously released paracrine stimulators/inhibitors. Data arising from studies using the perfused intestine which aim to elucidate the molecular mechanisms underlying secretion should, therefore, always be put into context with data obtained from other more specific models to increase the ability to establish causality. For instance, glucose-stimulated GLP-1 secretion from the GLP-1 secreting cell line GLUTag^{27,28} and from primary mouse L-cells depend on the activity of the glucose transporters (SGLT1 and GLUT2). Blocking these transporters in the perfused rat small intestine also attenuates secretion²⁰, meaning that it is likely that glucose-stimulated GLP-1 secretion is largely mediated by direct actions of glucose on the L-cell. Another important limitation of the isolated perfused intestine is that some of the lipids are difficult to study due to their hydrophobicity. Although it is possible to investigate the final products of lipid digestion (fatty acids, diacyl glycerols, lysophosphatidylglycerols, etc.) and although the preparation may be able to re-esterify the lipids intra-cellularly and perhaps pack them into chylomicrons, the transport of the chylomicrons out of the cells and their subsequent uptake by the lacteals of the villi is disrupted, since the lymph flow in the isolated gut cannot be

secured. Most likely, therefore, lipid absorption is halted once the absorbed products start to accumulate in the cells. The *in vitro* cell systems are even less suitable for lipid studies because of their lack of polarization. Obviously, this limitation is only relevant for lipids that are absorbed and transported via the lacteals, whereas those absorbed via the intestinal blood vessels are likely to be handled normally.

Protocol:

All studies were conducted with permission from the Danish Animal Experiments Inspectorate (2013-15-2934-00833) and the local ethical committee, in accordance with the guidelines of Danish legislation governing animal experimentation (1987) and the National Institutes of Health (publication number 85-23).

1. Experimental Animals

1.1 Obtain male Wistar rats (250 g) and house 2 per cage, with *ad libitum* access to standard chow and water, and maintain in a 12:12-h light-dark cycle.

Note: Allow animals at least one week of acclimatization.

2. Preoperative Preparations

2.1. Make perfusion buffer: Krebs-Ringer bicarbonate buffer supplemented with 0.1% BSA (fraction V), 5% dextran T-70, 3.5 mmol/L glucose, 10 mmol/L 3-isobutyl-1-methylxanthine, and 5 mmol/L pyruvate, fumarate, and glutamate (if needed); pH 7.4.

2.2. Prepare an adequate amount of perfusion buffer by filtering it through an appropriate size of filter and adjust pH to ~ 7.5 by dropwise addition of 5 M HCl.

2.3. Add 3-isobutyl-1-methylxanthine (IBMX) (if needed) directly to the buffer on the day of the study to a final concentration of 10 μ M.

Note: IBMX is a phosphodiesterase inhibitor that increases [cAMP]_i and thereby restores the sensitivity and responsiveness of the gut in terms of secreting hormones to a secretory stimulus.

2.4. Prepare test solution(s). Prepare vascular stimuli at a 20x higher concentration than the desired final concentration in filtered and pH-adjusted perfusion buffer. Prepare luminal test stimuli in isotonic saline in the final concentration.

2.5. Dissolve not readily soluble compounds in 100% dimethyl sulfoxide (DMSO) and dilute further in perfusion buffer or isotonic saline. For vascular stimuli, keep the final DMSO concentration at 1% or

below, as concentrations above this damage the intestine and may lead to unspecific gut hormone secretion. Measure pH and adjust to ~ 7.5 if needed.

3. Operation and Perfusion

Note: An illustration of a perfusion setup is provided in **Figure 1**.

3.1. Anesthetize the rats by use of an anesthetic regimen that can sustain surgical anesthesia and analgesia for 30-40 min by Hypnorm/Midazolam (0.079 mg of fentanyl citrate + 2.5 mg of fluanisone + 1.25 mg of midazolam, 0.3 mL/100 g of body weight).

3.2. Check for lack of reflexes (toe pinch), place the rat on the heated operating table and perform an incision of the skin to expose the intestine.

3.3. Expose the terminal part of the colon by moving the small intestine aside as much as possible. Tie of supplying vasculature to the colon and excise it gradually starting from the terminal part of the colon, moving towards the small intestine.

3.3.1. If only a certain part of the small intestine is required for perfusion (the upper half), excise non-required segments after tying off supplying vasculature. To minimize tissue damage, moisturize the intestine with isotonic saline and use swabs to remove connective tissue.

3.4. Insert a plastic tube (length: ~15 cm, outer diameter: ~ 0.4 cm) into the intestinal lumen (in the proximal part) and tie it properly using sutures. Flush carefully with isotonic saline (room temperature) to empty the lumen of chyme.

3.5. Perfuse the lumen with the isotonic saline at a flow of 0.25 mL/min, using a 10 mL syringe connected to a syringe pump.

3.6. Move the intestine aside so the upper mesenteric artery is accessible and remove connective and fat tissue to expose the artery.

3.7. Place two sutures under the mesenteric artery by using fine point forceps; one of the sutures is for lifting the artery to control bleeding once the artery has been cut and the other is for securing the catheter that is to be placed in the artery. Take caution not to perforate the artery.

3.8. Place two sutures under the portal vein for securing the metal catheter that is going to be placed in the vein for collection of perfusion effluent.

3.9. Before cutting the hole in the mesenteric artery, ensure that the catheter that is going to be inserted into the artery is filled with perfusion buffer to prevent air embolus formation.

3.10. Cut a small hole in the mesenteric artery using a pair of surgical scissors and insert the plastic catheter immediately after.

3.11. Immediately after the catheter has been secured, initiate perfusion of the gut by starting the roller pump (flow rate = 7.5 mL/min)

3.12. Confirm that the blood vessels in the gut turn pale within few seconds, and the portal vein turns pale.

3.13. Immediately after proper perfusion has been established, cut a hole in the portal vein, insert the metal catheter and secure it with the suture.

Note: The catheter can be difficult to place but lifting the vein up by cautiously pulling the most proximal suture helps.

3.14. Once the catheters are in place and perfusion output is satisfactory, kill the rat by diaphragm perforation, being careful not to rip out the catheters.

3.15. Collect perfusion output for 1 min and measure the volume. Start the perfusion pressure acquisition/recordings by click **Execute Experiment** in the pressure recording program.

3.16. Cover the gut with moistened tissue to prevent it from drying out during the experiment.

3.17. Ensure that the distal end of the intestine is not blocked so that the luminal effluent can exit, otherwise the intestine will swell, edema will develop, perfusion pressure will increase, and perfusion output will drop.

3.18. Leave the preparation for approximately 30 min before initiating the experiment.

Note: The secretory outputs of gut hormones are very unsteady for the first 15 min of perfusion, so this equilibration step is needed to get a steady baseline.

4. Experiment

4.1. After approximately 30 min of perfusion, start the experiment by collecting the first baseline sample using a fraction collector. Collect samples at the desired time interval (*e.g.*, every min, 6.5-7.5 mL is usually collected) and place them on ice within few min.

4.2. Inspect the bubble trap regularly and, if emptied, refill it with perfusion buffer.

4.2.1 Collect the buffer through the three-way cock-valve immediately before it enters the organ and from the catheter inserted in the portal vein (after it has been perfused through the organ to confirm

that the organ is metabolically active. Collect samples at the start and end of experiment to assess viability throughout the experiment.

4.2.2. Measure samples quickly, with an automated blood-gas analyzer, as most plastic contains/syringes are not completely airtight, giving rise to exchange with the atmospheric air.

4.3. After 10-15 min of baseline collection, stimulate with the first test substance. Administer intra-arterial stimulations with a syringe pump through a three-way stopcock (flow = 0.350 mL/min).

4.4. Perform luminal stimulations by an initial bolus injection (2.5 mL/min over the first 5 min), to replace the isotonic saline that is already in the lumen, followed by administration of the test solution a lower flow rate (0.5 mL/min).

4.5. To ensure that the lumen is quickly emptied of test substance once the luminal stimulation period is over, flush the intestinal lumen with isotonic saline by applying same flow rates as above.

4.6. Collect baseline samples for 15-30 min before the next test substance is administered. Depending on the protocol, 2-3 test stimuli can usually be included per experiment. If the experimental protocol includes activation/inhibition of a given molecular site simultaneously with administration of a given secretagogue, always pre-stimulate with the activator/inhibitor 10-15 min before the administration of the secretagogue to ensure that the molecular site is inhibited at the very beginning of secretagogue infusion.

4.7. At the end of the protocol, administer (5-10 min) a suitable positive control to test for responsiveness of the preparation and collect 10-15 min baseline samples after the stimulation period.

Note: Several test substances can be used as positive control, *e.g.*, stimuli for increasing $[cAMP]_i$ (*e.g.*, forskolin or IBMX), $[Ca^{2+}]_i$ (*e.g.*, bombesin or neuromedin C), depolarizing agents (*e.g.*, 30-50 mM KCl) or more physiologically relevant stimuli such as macronutrients: glucose, peptones, amino acids, etc. However, the choice of positive control depends on the experimental outcome. Glucose is for instance a poor cholecystinin (CCK) secretagogue whereas bombesin is not a robust secretagogue for glucose-dependent insulinotropic peptide (GIP) secretion²⁹.

4.8. After the end of experiment, excise the perfused gut, weigh it and measure its length. Put it in paraformaldehyde and store it (4°C) for potential later histochemical analysis of tissue integrity/damage, for instance by H&E staining.

5. Biochemical Measurements

5.1. Quantify concentrations of secreted peptides in the venous effluent by use of an in-house or commercially available radioimmunoassays (RIA) or ELISA-assays. For studies that investigate

intestinal absorption, quantify the molecule of interest, *e.g.*, glucose or amino acids, in the venous effluent.

Note: The perfusate is usually a good basal buffer for most analyses, including assays that relies on enzymatic reactions (such as quantification of glucose by the glucoseoxidase method).

6. Data Analysis

6.1. Present data in different ways, for instance as a time-concentration graph showing the actual secretory output (flow x concentration) and as column plot depicting the total secretory output during baseline and response periods (usually 10-15 time points).

6.2. Plot the actual measured concentration of the respective hormones as concentration units. (pmol/L),

Note: It is preferable to instead express data as output (fmol/min) because with this model, in contrast to *in vivo* studies, the obtained values are the actual secretory output (because of the constant collection of perfusion effluent).

6.3. Depending on the number of groups to be analyzed statistically, use two-tailed paired t-test (two groups) or one-way ANOVA for repeated measurements (more than two groups) followed by an appropriate post-hoc test for multiple comparisons.

REPRESENTATIVE RESULTS

The ability to determine whether a given stimulus causes secretion of the gut hormone of interest relies on a steady baseline secretion. Furthermore, if no response to the stimulus is observed, a robust secretory response to the positive control must be evident to exclude that the lack of response to the test stimulus does not reflect a general lack of responsiveness. **Figures 2A** and **2B** shows an example of good quality data; GLP-1 secretion from the isolated perfused rat small intestine are shown at 1-min intervals (means \pm SEM). At basal conditions secretion is steady; both before and after administration of the test stimulus (insulin), and a robust secretory response to the positive control (bombesin (BBS)) is evident. In addition, averaged GLP-1 secretion at basal conditions (during the respective baseline periods preceding insulin or BBS administration) as well as averaged secretion during insulin and BBS stimulation are shown as bar graphs (means \pm SEM). Secretion was tested for statistical significance by one-way ANOVA for repeated measurements. Based on these combined data, it can be concluded that intra-arterial insulin does not stimulate GLP-1 secretion from the isolated perfused rat small intestine.

Figures 2C and **2D** shows an example of GLP-1 secretion from the isolated perfused rat small intestine. Unlike **Figures 2A** and **2B**, these data are of poor-quality; the secretion is unsteady at basal conditions and drifts upwards throughout in a manner that appears to be unrelated to test substance administrations (intra-luminal and intra-arterial fructose, respectively) and the positive control, BBS,

does not result in statistical significant increased GLP-1 secretion. It is, therefore, impossible to conclude whether the fructose stimulations give rise to GLP-1 secretion, *e.g.*, is the increased GLP-1 secretion at the end of the vascular fructose stimulation a fructose-mediated response or not.

FIGURE LEGENDS

Figure 1. An example of a perfusion setup. The system consists of a plexiglass stand, a heated operating table, a heat exchanger with build in bubble trap, a pressure gauge and spindle pump for perfusion pressure adjustment. The perfusion system is connected to a thermostatic circulator which heats the gassed (95% O₂, 5% CO₂) perfusion buffer to 37 °C. In addition, perfusion pressure is recorded continuously and transduced by the pressure recording transducer and visualized and saved on a PC with suitable software.

Figure 2. Data from the isolated perfused rat small intestine. A, B: an example of a well-performed experiments and reliable data, C, D: an example of sub-optimal data where perfusion pressure increased, and perfusion output decreased dramatically over the time course of the study. A: GLP-1 (total) output (fmol/min) is shown at basal conditions and in response to intra-arterial insulin administration (200 and 1000 pM, as indicated). Bombesin (BBS), a well-known, potent GLP-1 secretagogue, was infused intra-arterially at the end of the experiment to control for responsiveness (pos. control). Data are presented as means \pm SEM, $n = 4$.

DISCUSSION:

The isolated perfused rat small intestine is a powerful research tool that allows the dynamics and molecular mechanisms underlying gut hormone secretion to be studied in detail. The most critical step for the successful production of data with this model is the surgical operation. Handling of the gut will inevitably cause some damage to the intestine and should therefore be kept to an absolute minimum. Even more importantly, the speed of operation is key, particularly with regard to the time for the catheter placement in the mesenteric artery. Our experience is that the catheter should be successfully placed, and the perfusion should be initiated within a couple of min after having cut the hole in the vessel. The placement of the catheters is the most challenging part of the operation and is complicated by the small size of the mesenteric artery and the thin wall of the portal vein, and this step requires some practice. Quick insertion of the venous catheter is, however, not as urgent as the case for the mesenteric artery, as the gut is now being perfused and kept alive. The next critical step is to perform the experiment. If the operation was successfully performed, the perfused gut will usually thrive and be responsive for up to 3 h, and perfusion pressure and output will typically remain constant over the entire experiment. The most important factor for a successful experiment at this stage is to avoid bubbles getting into the system, since this causes air embolization which either instantly reduces or eliminates the perfusion output. As the perfusion buffer contains BSA and is gassed to ensure sufficient oxygen delivery to the perfused gut, it is difficult to prevent the formation of bubbles entirely. Bubbles should, however, be trapped in the systems' bubble trap, but this gradually empties over time (the more bubbles, the faster emptying) and it is therefore important to keep a close watch on the bubble trap and refill it with perfusion buffer when needed. It is also

important to keep the perfusate pH below 7.5 – at increasing pH, calcium carbonate precipitates may form, obstructing capillary flow and causing a serious rise in perfusion pressure.

The perfused intestine is a rather robust preparation, but it does not tolerate high concentrations of detergents such as bile acids, ethanol and DMSO. Therefore, the use of detergents should preferably be avoided but is sometimes needed to get poorly soluble compounds into solution. The perfused gut generally tolerates detergents administered intra-luminally better than intra-vascularly. For instance, administration of 1 mM taurodeoxycholic acid (a secondary, conjugated bile acid) was tolerated well when infused intraluminally but instantly resulted in blocked perfusion output when delivered intra-arterially². For vascular stimulations, keep the final DMSO concentration below 1% to avoid unspecific secretory responses (DMSO stimulates, for instance, GLP-1 secretion) and to avoid causing tissue damage resulting in increased perfusion pressure and decreased perfusion output. Experiments should be disregarded if the perfusion output decreases by more than 20% over the course of the study, if the perfusion pressure increases more than 20% or if edema develops. Adherence to these macroscopic success criteria (including quick insertion of the catheter in the mesenteric artery) usually results in good quality in ~14/15 experiments.

After completing the experiment, the next critical procedure is to choose the appropriate method and assay for quantification of the hormone(s) of interest. High through-put assaying of peptide hormones can be carried out using immunoassays: radioimmunoassay or ELISA. At any rate, it is highly recommended to validate the respective assays before using them for sample quantification, as not all commercially available assays perform satisfactorily with respect to sensitivity, specificity and accuracy (for examples regarding GLP-1³⁰). With respect to specificity, cross-reactivity is, as always, a concern. Unspecific interference and matrix effects are generally less pronounced with artificial perfusates compared to plasma. With regards to sensitivity, it is often much easier to obtain reliable data from perfusions than from *in vivo* studies as the peptide concentrations often are higher because the perfusion effluent is not diluted into the systemic circulation and because elimination processes (by the liver/lung/kidney) are avoided. Typically, baseline concentrations in venous effluents lie within the lower working range of most assays (in case of GLP-1 (total), neurotensin (total) and PYY (total): 8-15 pmol/L) while stimulated responses can reach as high as 200-300 pmol/L³.

In comparison, baseline values of the same hormones in plasma from healthy humans, rat or mice are typically 5-10 pmol/L whereas response values are 15-30 pmol/L^{3,31}.

If the predefined success criteria are adhered to, the generated perfusion data are usually of good quality and the statistical analysis is then straightforward. Compared to secretion of glucagon, insulin and somatostatin from the isolated perfused rat or mouse pancreas, the basal secretion of gut hormones is steady, and rather similar between experiments regarding measured concentrations, and the secretion is not clearly pulsatile. Collectively, the variation in the data set is therefore minimal and a sample size as low as three perfusion experiments is often sufficient to reach statistical significance. However, to standardize and avoid type-2-errors, as well as to reduce the possibility of overlooking less well-pronounced responses, a sample size of six to eight is recommended.

In summary, the isolated perfused rat small intestine is an important, physiologically relevant, experimental model that can be used to investigate the direct effects of a given substance on gut hormone secretion. Important fundamental questions, such as where in the gut a secretagogue stimulates secretion, whether it stimulates secretion through activation of lumenally or basolaterally located sensors, and which molecular sensors are activated and thus responsible for the secretion may be addressed in detail with this model. It should, however, be recognized that the uncoupling of the gut from the donor animal may, for some study questions, be of relevance. For instance, the gut interacts closely with the liver (the gut-liver axis) and the brain (the gut-brain axis), and mechanisms that rely on this cross-talk therefore cannot be investigated with this model. The quality of the operation is the critical factor for data quality and the most important factors for a successful operation are to keep handling of the gut to a minimum and to quickly start perfusion of the gut once the mesenteric artery has been cut. It is our experience that it takes 2-4 months of practice before data of good quality are produced. However, once the technique has been learned, the possibilities of this method are almost endless and only limited by the solubility of the test substances and any potential damaging effects test substances may have on the perfused tissue.

ACKNOWLEDGEMENTS:

This work was supported by an unrestricted grant to Prof. Jens Juul Holst from the Novo Nordisk Center for Basic Metabolic Research (Novo Nordisk Foundation, Denmark), a separate grant from the Novo Nordisk Foundation for doing rodent perfusion studies (grant no. NNF15OC0016574), a grant to Prof. Holst from the European Research Council (Grant no.695069) and the European Union's Seventh Framework Programme for Research, Technological Development, and Demonstration Activities (Grant No. 266408) as well as a postdoc grant to Rune E. Kuhre from the Lundbeck Foundation (R264-2017-3492). We thank Jenna E. Hunt and Carolyn F. Deacon for careful proofreading.

DISCLOSURES:


The authors of this work declare no potential conflicts of interest relevant to this article.


References:

1. Rindi, G., Leiter, A.B., Kopin, A.S., Bordi, C. & Solcia, E. The "normal" endocrine cell of the gut: changing concepts and new evidences. *Annals of the New York Academy of Sciences*. **1014**, 1-12 (2004).
2. Brighton, C.A., *et al.* Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors. *Endocrinology*. **156**, 3961-3970 (2015).
3. Kuhre, R.E., *et al.* Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. *Molecular Metabolism*. (2018).
4. Roberge, J.N. & Brubaker, P.L. Secretion of Proglucagon-Derived Peptides in Response to Intestinal Luminal Nutrients. *Endocrinology*. **128**, 3169-3174 (1991).
5. Brubaker, P.L., Schloos, J. & Drucker, D.J. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. *Endocrinology*. **139**, 4108-4114 (1998).

- 502 6. Jacobsen, S., *et al.* Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and
503 Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects. *Obesity*
504 *Surgery*. **22**, 1084-1096 (2012).
- 505 7. Kuhre, R.E., Frost, C.R., Svendsen, B. & Holst, J.J. Molecular mechanisms of glucose-stimulated
506 GLP-1 secretion from perfused rat small intestine. *Diabetes*. **64**, 370 (2014).
- 507 8. Svendsen, B. & Holst, J.J. Regulation of gut hormone secretion. Studies using isolated perfused
508 intestines. *Peptides*. **77**, 47-53 (2016).
- 509 9. Ratner, C., *et al.* Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in
510 Gastric Bypass Surgery. *Endocrinology*. **157**, 3482-3492 (2016).
- 511 10. Wewer Albrechtsen, N.J., *et al.* Dynamics of glucagon secretion in mice and rats revealed using
512 a validated sandwich ELISA for small sample volumes. *American Journal of Physiology*
513 *Endocrinology and Metabolism*. **311**, E302-309 (2016).
- 514 11. Vilsboll, T., Agerso, H., Krarup, T. & Holst, J.J. Similar elimination rates of glucagon-like peptide-
515 1 in obese type 2 diabetic patients and healthy subjects. *The Journal of Clinical Endocrinology*
516 *and Metabolism*. **88**, 220-224 (2003).
- 517 12. Windelov, J.A., *et al.* Why is it so difficult to measure glucagon-like peptide-1 in a mouse?
518 *Diabetologia*. **60**, 2066-2075 (2017).
- 519 13. Gorboulev, V., *et al.* Na⁺-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose
520 Absorption and Glucose-Dependent Incretin Secretion. *Diabetes*. **61**, 187-196 (2012).
- 521 14. Kuhre, R.E., Bechmann, L.E., Wewer Albrechtsen, N.J., Hartmann, B. & Holst, J.J. Glucose
522 stimulates neurotensin secretion from the rat small intestine by mechanisms involving SGLT1
523 and GLUT2, leading to cell depolarization and calcium influx. *American Journal of Physiology*
524 *Endocrinology and Metabolism*. **308**, E1123-1130 (2015).
- 525 15. Kuhre, R.E., Christiansen, C.B., Saltiel, M.Y., Wewer Albrechtsen, N.J. & Holst, J.J. On the
526 relationship between glucose absorption and glucose-stimulated secretion of GLP-1,
527 neurotensin, and PYY from different intestinal segments in the rat. *Physiological Reports*.
528 **5**(2017).
- 529 16. Svendsen, B., *et al.* An analysis of cosecretion and coexpression of gut hormones from male rat
530 proximal and distal small intestine. *Endocrinology*. **156**, 847-857 (2015).
- 531 17. Goldspink, D.A., *et al.* Mechanistic insights into the detection of free fatty and bile acids by
532 ileal glucagon-like peptide-1 secreting cells. *Molecular Metabolism*. **7**, 90-101 (2018).
- 533 18. Sun, E.W., *et al.* Mechanisms Controlling Glucose-Induced Glp-1 Secretion in Human Small
534 Intestine. *Diabetes*. (2017).
- 535 19. Kuhre, R.E., *et al.* Peptide production and secretion in GLUTag, NCI-H716 and STC-1 cells: a
536 comparison to native L-cells. *Journal of Molecular Endocrinology*. **56**, 11 (2016).
- 537 20. Reimann, F., *et al.* Glucose sensing in L cells: a primary cell study. *Cell Metabolism*. **8**, 532-539
538 (2008).
- 539 21. Reimann, F., *et al.* Characterization and functional role of voltage gated cation conductances in
540 the glucagon-like peptide-1 secreting GLUTag cell line. *The Journal of Physiology*. **563**, 161-175
541 (2005).
- 542 22. Kuhre, R.E., *et al.* Fructose stimulates GLP-1 but not GIP secretion in mice, rats and humans.
543 *American journal of physiology. Gastrointestinal and Liver Physiology*. **306**, G622-G630 (2014).

- 544 23. Reimann, F., Tolhurst, G. & Gribble, Fiona M. G-Protein-Coupled Receptors in Intestinal
545 Chemosensation. *Cell Metabolism*. **15**, 421-431 (2012).
- 546 24. Parker, H.E., *et al.* Molecular mechanisms underlying bile acid-stimulated glucagon-like
547 peptide-1 secretion. *British Journal of Pharmacology*. **165**, 414-423 (2012).
- 548 25. Petersen, N., *et al.* Generation of L cells in mouse and human small intestine organoids.
549 *Diabetes*. **63**, 410-420 (2014).
- 550 26. Parker, H., *et al.* Predominant role of active versus facilitative glucose transport for glucagon-
551 like peptide-1 secretion. *Diabetologia*. **55**, 2445-2455 (2012).
- 552 27. Reimann, F. & Gribble, F.M. Glucose-Sensing in Glucagon-Like Peptide-1-Secreting Cells.
553 *Diabetes*. **51**, 2757-2763 (2002).
- 554 28. Drucker, D.J., Jin, T., Asa, S.L., Young, T.A. & Brubaker, P.L. Activation of proglucagon gene
555 transcription by protein kinase-A in a novel mouse enteroendocrine cell line. *Molecular*
556 *Endocrinology (Baltimore, Md.)*. **8**, 1646-1655 (1994).
- 557 29. Svendsen, B., *et al.* GLP1- and GIP-producing cells rarely overlap and differ by bombesin
558 receptor-2 expression and responsiveness. *The Journal of Endocrinology*. **228**, 39-48 (2016).
- 559 30. Bak, M.J., *et al.* Specificity and sensitivity of commercially available assays for glucagon-like
560 peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. *Diabetes, Obesity &*
561 *Metabolism*. **16**, 1155–1164 (2014).
- 562 31. Jacobsen, S.H., *et al.* Effects of gastric bypass surgery on glucose absorption and metabolism
563 during a mixed meal in glucose-tolerant individuals. *Diabetologia*. **56**, 2250-2254 (2013).





Name of Reagent/ Equipment	Company	Catalog Number
<i>Chemicals for perfusion buffer</i>		
Bovine serum albumin (BSA)	Merck	1.12018.0500
Calcium chloride dihydrate (CaCl ₂ x 2 H ₂ O)	Merck	102382
Dextran 70	Pharmacosmos	40014
Fumaric acid disodium salt (C ₄ H ₂ Na ₂ O ₄)	Sigma Aldrich	F9642
Glucose (C ₆ H ₁₂ O ₆)	Merck	108342
Magnesium sulfate heptahydrate (MgSO ₄)	Merck	105886
Potassium chloride (KCl)	Merck	104936
Potassium dihydrogen phosphate (KH ₂ PO ₄)	Merck	104873
Pyruvic acid sodium salt (C ₃ H ₃ NaO ₄)	Merck	106619
Sodium bicarbonate (NaHCO ₃)	Merck	
Sodium chloride (NaCl)	Merck	106404
Sodium L-glutamate monohydrate (C ₅ H ₈ NNaO ₄ x H ₂ O)	Merck	106445
<i>Perfusion equipment</i>		
Universal perfusion system	Harvard Bioscience, Inc.	732316
BASIC UNIT UNIPER UP-100, TYPE 834	Harvard Bioscience, Inc.	
Roller Pump, with four channels	Harvard Bioscience, Inc.	730100
Windkessel	Harvard Bioscience, Inc.	732068
Thermostatic Circulator, Bath Volume 3L, 230V/50Hz	Harvard Bioscience, Inc.	730125
Operating table, heated on tripod stand, type 873	Harvard Bioscience, Inc.	733776

Cannula with basked, OD= 2.0mm, ID=
1.0mm

Harvard Bioscience,
Inc.

733313

Comments/Description



1 Alewife Center #200
 Cambridge, MA 02140
 tel. 617.945.9051
 www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Investigation of the mechanisms underlying gut hormone secretion using

Author(s):

Rune E. Kuhre and Jens J. Holst

isolated
 perfused
 rat small
 intestine.

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:

Jens Juul Holst

Department:

Department of Biomedical Sciences and NNF Centre

Institution:

University of Copenhagen

Article Title:

Investigation of the molecular mechanisms underlying gut

Signature:

[Handwritten Signature]

Date:

05/30-18

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

for basic
metabolic
research
(research
hormone
secretion
using
isolated
permeable
rat small
intestine

**Rebuttal Letter,
Second revision of JoVE58533R1**

Dear Editor,

Thanks for your careful reading and commenting on our manuscript. Please find our responses (in italics) to your individual comments below.

Sincerely,

Rune E Kuhre and Jens J Holst

Editorial comments:

1. The editor has formatted the manuscript to match the journal's style. Please retain the same. *Thanks.*
2. Please address all specific comments marked in the manuscript. *All comments have been addressed, see corrections in text as well as our inserted comments; note that for some reasons our initials are not indicated in the comments as they were converted by Word to the same initials as the editor; "A".*
3. For the protocol section, please do not generalize the experiment, please provide all specifics of how you did your experiment with all necessary details. *Thank you, we have increased the number of details.*
4. Please use imperative tense as if directing someone to do the experiment. Please ensure that each step is a hard experimental step. *Thanks for pointing this to our attention. We have deleted some steps that were not hard experimental steps and have changed to imperative tense throughout the protocol section.*
5. The numbering of the steps and substeps are off. Please check. *Now corrected, thanks.*
6. Once formatted, please check that the protocol is no more than 10 pages in length. *The protocol is now 6 pages.*

7. Please highlight 2.75 pages including heading and spacings for filming purpose. Please ensure that this should form the most cohesive story of the protocol presented. *Done.*

8. Please proofread the manuscript carefully before submission. *The manuscript has been carefully proofread.*